众兴菌业(002772) - 2023 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2023 was ¥1,931,077,659.25, a decrease of 1.99% compared to ¥1,970,274,412.53 in 2022[19]. - The net profit attributable to shareholders for 2023 was ¥159,581,340.77, reflecting a 0.78% increase from ¥158,351,860.28 in 2022[19]. - The net profit after deducting non-recurring gains and losses decreased by 26.74% to ¥131,236,926.42 from ¥179,126,371.50 in 2022[19]. - The cash flow from operating activities for 2023 was ¥502,479,058.21, an increase of 1.78% compared to ¥493,702,411.60 in 2022[19]. - The total assets at the end of 2023 were ¥6,073,765,300.40, down 7.54% from ¥6,569,141,307.16 at the end of 2022[19]. - The basic earnings per share for 2023 were ¥0.39, a decrease of 2.50% from ¥0.40 in 2022[19]. - The weighted average return on equity for 2023 was 4.84%, slightly down from 4.93% in 2022[19]. - The company reported a net profit of ¥198,103,761.13 in Q1 2023, but incurred losses in Q2, Q3, and Q4[23]. - The total non-recurring gains and losses for 2023 amounted to ¥28,344,414.35, compared to a loss of ¥20,774,511.22 in 2022[25]. - Total revenue for 2023 was approximately ¥1.93 billion, a decrease of 1.99% compared to ¥1.97 billion in 2022[58]. Dividend Distribution - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares to all shareholders, based on a total of 393,241,359 shares[5]. - The total number of shares for the cash dividend distribution is based on 393,241,359 shares, excluding repurchased shares[160]. - The cash dividend distribution represents 100% of the total profit distribution amount[160]. - The company distributed a cash dividend of 3.00 CNY per 10 shares, totaling 118 million CNY for the 2022 fiscal year[187]. Production and Operations - The company operates in the edible mushroom cultivation industry, focusing on modern agricultural practices and factory-based production[30]. - The company's daily production capacity for edible mushrooms reached 1,175 tons as of December 31, 2023, with 805 tons for enoki mushrooms and 360 tons for button mushrooms[34]. - The company produced a total of 332,200 tons of edible mushrooms in 2023, an increase of 1.54% compared to 2022[56]. - The company has established production bases in multiple provinces, including Gansu, Shaanxi, and Shandong, to support its operations[36]. - The company operates a factory-based production model, allowing for year-round production and stable supply, which enhances its ability to withstand market risks[41]. Market Dynamics - The overall price level of agricultural products in China decreased by 2.3% in 2023, with specific declines in various categories, including a 4.1% drop in vegetable prices[33]. - The competitive landscape in the edible mushroom industry is intensifying, influenced by supply-demand dynamics and raw material costs[40]. - The market for edible mushrooms is characterized by seasonal price fluctuations, with the second quarter typically being a low-demand period[33]. - The company anticipates risks related to price declines due to increased competition in the edible mushroom industry and plans to enhance brand recognition to mitigate these risks[107]. - The company recognizes the potential for sales price and profit fluctuations due to seasonal demand variations and aims to diversify its product offerings to reduce the impact of these fluctuations[108]. Research and Development - The company added 13 new patents during the reporting period, while 20 patents expired, with no significant changes in other important intangible assets[50]. - The company has successfully implemented a technical breakthrough in the cultivation of Cordyceps sinensis, enhancing product quality and efficiency[56]. - R&D investment increased by 24.09% to ¥12,922,343.53 in 2023, compared to ¥10,413,631.63 in 2022, with the R&D investment accounting for 0.67% of operating revenue[69]. - The number of R&D personnel decreased by 11.11% to 160 in 2023 from 180 in 2022, with a notable increase in the number of bachelor's degree holders from 19 to 38[69]. - The company is focused on building an independent strain library to support high-quality strain supply for domestic and international markets[103]. Environmental Compliance - The company adheres to multiple environmental protection laws and industry standards, including the Environmental Protection Law and the Air Pollution Prevention and Control Law[176]. - The company has established a wastewater treatment plant with a processing capacity of 600 m³/d, utilizing the A/O biological contact oxidation process, and currently meets the discharge standards[179]. - The company reported that the concentration of COD in treated wastewater is 47.75 mg/L, which is below the standard limit of 100 mg/L, with an annual discharge of 8.26 tons[179]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[182]. - The company actively participates in social responsibility initiatives and promotes clean production strategies to contribute to sustainable environmental development[183]. Governance and Management - The company has maintained a stable management team with no resignations or dismissals reported during the current term[129]. - The company has established a transparent performance evaluation and incentive mechanism, enhancing management effectiveness[121]. - The company has independent financial management, with a complete accounting system and no interference from controlling shareholders[123]. - The company held 4 shareholder meetings and 12 board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[119]. - The company has improved its internal control systems by revising key governance documents, enhancing compliance and operational efficiency[121]. Employee Relations - The company has implemented an employee stock ownership plan, with a total of 9,000,000 shares held, accounting for 2.29% of the company's total equity[164]. - The company emphasizes internal talent development through a structured training program to enhance employee skills and core competitiveness[156]. - The total number of employees at the end of the reporting period was 5,761, with 4,996 in production, 66 in sales, 336 in technical roles, 45 in finance, and 231 in administration[153]. - The company's compensation policy emphasizes efficiency, fairness, and performance, with salaries comprising basic, position, duty, performance wages, and various bonuses[155]. - The company maintained stable employment by ensuring no layoffs or salary reductions, contributing to job security for its workforce[198].